Notch3 overexpression enhances progression and chemoresistance of urothelial carcinoma
Metrics: PDF 1650 views | HTML 1699 views | ?
Heng Zhang1,2, Limei Liu1, Chungang Liu1, Jinhong Pan2, Gensheng Lu2, Zhansong Zhou2, Zhiwen Chen2, Cheng Qian1
1Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing 400038, China
2Department of Urology, Southwest Hospital, Third Military Medical University, Chongqing 400038, China
Cheng Qian, email: firstname.lastname@example.org
Zhiwen Chen, email: email@example.com
Keywords: Notch3, urothelial cancer, cisplatin, histone deacetylase, chemoresistance
Received: March 14, 2016 Accepted: December 12, 2016 Published: March 13, 2017
Abnormal activation of Notch signaling is involved in the etiology of various diseases, including cancer, but the association between Notch3 expression in urothelial cancer and clinical outcome remains unclear, and the molecular mechanisms underlying Notch3 signaling activation are not well defined. In this study we examined 59 urothelial cancer patients and found that Notch3 was more highly expressed in human urothelial cancer tissues than in non-tumorous bladder tissue samples, with Notch3 overexpression being associated with poor clinical outcome. Notch3 knockdown resulted in decreased proliferation of urothelial cancer cells in vitro and decreased xenograft tumor growth in vivo. In addition, Notch3 knockdown rendered urothelial cancer cells more sensitive to cisplatin. Furthermore, suberoylanilide hydroxamic acid (SAHA, a histone deacetylase [HDAC] inhibitor) induced acetylation of NOTCH3, downregulated Notch 3, prevented urothelial cancer cell proliferation, and induced cell cycle arrest. Taken together, these data suggested that Notch 3 overexpression promotes growth and chemoresistance in urothelial cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.